8-K: Nektar Therapeutics Reports Positive Q4 2024 Financial Results and Provides Pipeline Update

Nektar Therapeutics announces improved financial results for Q4 and full year 2024, driven by increased revenue and reduced operating expenses, alongside promising progress in its immunology pipeline.

Summary

• Nektar Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company's cash and investments in marketable securities totaled $269.1 million as of December 31, 2024, compared to $329.4 million at the end of 2023.
• Nektar anticipates that its current cash reserves will support strategic development activities and operations into the fourth quarter of 2026.
• Revenue for the fourth quarter of 2024 was $29.2 million, up from $23.9 million in the same period of 2023.
• Full-year revenue for 2024 reached $98.4 million, compared to $90.1 million in 2023.
• Total operating costs and expenses for the fourth quarter of 2024 were $14.8 million, significantly lower than the $57.4 million reported in the fourth quarter of 2023.
• For the full year 2024, operating costs and expenses totaled $203.6 million, a decrease from $353.8 million in 2023.
• The reduction in operating costs was primarily attributed to a $40.4 million gain from the sale of the Huntsville manufacturing facility and decreases in restructuring and impairment costs.
• Net income for the fourth quarter of 2024 was $7.3 million, or $0.03 per share, compared to a net loss of $42.1 million, or $0.22 per share, in the fourth quarter of 2023.
• The net loss for the full year 2024 was $119.0 million, or $0.58 per share, compared to a net loss of $276.1 million, or $1.45 per share, in 2023.
• Enrollment is complete for the atopic dermatitis and alopecia areata Phase 2b trials, with topline data expected in the second and fourth quarters of 2025, respectively.

Sentiment

Score: 7

Explanation: The sentiment is positive due to improved financial results, progress in clinical trials, and a strong cash position. However, the company still reported a net loss for the full year, which tempers the overall optimism.

Positives

• Cash position is strong, expected to fund operations into Q4 2026.
• Revenue increased for both the fourth quarter and the full year.
• Operating costs and expenses decreased significantly, leading to improved profitability.
• The company achieved net income in Q4 2024, a significant turnaround from the previous year's loss.
• Enrollment is complete for key Phase 2b trials of rezpegaldesleukin.
• FDA granted Fast Track designation for rezpegaldesleukin in atopic dermatitis.
• Nektar entered into a new clinical trial agreement with TrialNet for type 1 diabetes research.
• The sale of the Huntsville manufacturing facility generated a $40.4 million gain.

Negatives

• Despite improved financials, the company still reported a net loss for the full year 2024.
• Cash and investments decreased from $329.4 million to $269.1 million year-over-year.

Risks

• The success of rezpegaldesleukin and other pipeline candidates is subject to the inherent risks of clinical development, including potential safety and efficacy concerns.
• Delays in clinical trial timelines or regulatory approvals could impact the company's future prospects.
• The company's reliance on third-party manufacturing for PEG reagents could pose a supply chain risk.
• The forward-looking statements are subject to uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of the company's control.

Future Outlook

Nektar expects its cash and marketable securities to support operations into the fourth quarter of 2026 and anticipates topline data from Phase 2b trials of rezpegaldesleukin in atopic dermatitis and alopecia areata in the second and fourth quarters of 2025, respectively. The company also plans to submit an IND for NKTR-0165 in the second half of 2025.

Management Comments

• The significant progress we made last year in advancing our immunology pipeline positions us for two value-creating data milestones in 2025, said Howard W. Robin, President and CEO of Nektar.
• This program is poised to emerge as the first T regulatory cell treatment option to help the millions of patients battling these chronic autoimmune disorders, continued Robin.

Industry Context

Nektar's focus on immunology and autoimmune diseases aligns with a growing trend in the biotechnology industry, with increasing investment and research in these areas. The development of rezpegaldesleukin as a potential first-in-class regulatory T cell stimulator could position Nektar as a leader in this emerging field.

Comparison to Industry Standards

• Comparing Nektar's cash runway to similar biotech companies, a cash position that supports operations into Q4 2026 is relatively strong, providing financial flexibility for ongoing clinical trials and research.
• For example, companies like Alder BioPharmaceuticals (acquired by Lundbeck) and Principia Biopharma (acquired by Sanofi) were acquired with similar cash runways and promising clinical assets.
• Nektar's focus on Treg modulation is comparable to efforts by companies like Kyverna Therapeutics and TScan Therapeutics, which are also developing therapies targeting immune regulation.
• The Phase 2b trial design for rezpegaldesleukin in atopic dermatitis, with a sample size of 396 patients, is consistent with industry standards for mid-stage clinical trials in this indication, similar to trials conducted by Regeneron and LEO Pharma.

Stakeholder Impact

• Shareholders will likely react positively to the improved financial results and pipeline progress.
• Employees may feel more secure due to the company's strong cash position and positive outlook.
• Patients with autoimmune diseases may benefit from the potential development of new treatments.
• The sale of the Huntsville manufacturing facility impacts employees at that location, but Nektar has entered into manufacturing supply agreements with the new company.

Next Steps

• Report topline data for rezpegaldesleukin in atopic dermatitis Phase 2b trial in the second quarter of 2025.
• Report topline data for rezpegaldesleukin in alopecia areata Phase 2b trial in the fourth quarter of 2025.
• Submit IND for NKTR-0165 in the second half of 2025.

Key Dates